These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 23196615

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Inflammation stimulates remyelination in areas of chronic demyelination.
    Foote AK, Blakemore WF.
    Brain; 2005 Mar; 128(Pt 3):528-39. PubMed ID: 15699059
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Oligodendroglia in cortical multiple sclerosis lesions decrease with disease progression, but regenerate after repeated experimental demyelination.
    Rodriguez EG, Wegner C, Kreutzfeldt M, Neid K, Thal DR, Jürgens T, Brück W, Stadelmann C, Merkler D.
    Acta Neuropathol; 2014 Aug; 128(2):231-46. PubMed ID: 24563023
    [Abstract] [Full Text] [Related]

  • 26. Remyelination in multiple sclerosis.
    Chari DM.
    Int Rev Neurobiol; 2007 Aug; 79():589-620. PubMed ID: 17531860
    [Abstract] [Full Text] [Related]

  • 27. Histamine Receptor 3 negatively regulates oligodendrocyte differentiation and remyelination.
    Chen Y, Zhen W, Guo T, Zhao Y, Liu A, Rubio JP, Krull D, Richardson JC, Lu H, Wang R.
    PLoS One; 2017 Aug; 12(12):e0189380. PubMed ID: 29253893
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination.
    Watzlawik J, Warrington AE, Rodriguez M.
    Expert Rev Neurother; 2010 Mar; 10(3):441-57. PubMed ID: 20187865
    [Abstract] [Full Text] [Related]

  • 32. Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials.
    Sutiwisesak R, Burns TC, Rodriguez M, Warrington AE.
    Expert Opin Investig Drugs; 2021 Aug; 30(8):857-876. PubMed ID: 34126015
    [Abstract] [Full Text] [Related]

  • 33. Cerebrospinal fluid of progressive multiple sclerosis patients reduces differentiation and immune functions of oligodendrocyte progenitor cells.
    Zveik O, Fainstein N, Rechtman A, Haham N, Ganz T, Lavon I, Brill L, Vaknin-Dembinsky A.
    Glia; 2022 Jun; 70(6):1191-1209. PubMed ID: 35266197
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination.
    Lau LW, Keough MB, Haylock-Jacobs S, Cua R, Döring A, Sloka S, Stirling DP, Rivest S, Yong VW.
    Ann Neurol; 2012 Sep; 72(3):419-32. PubMed ID: 23034914
    [Abstract] [Full Text] [Related]

  • 36. Inhibitory milieu at the multiple sclerosis lesion site and the challenges for remyelination.
    Galloway DA, Gowing E, Setayeshgar S, Kothary R.
    Glia; 2020 May; 68(5):859-877. PubMed ID: 31441132
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Multiple sclerosis: remyelination in acute lesions.
    Raine CS, Wu E.
    J Neuropathol Exp Neurol; 1993 May; 52(3):199-204. PubMed ID: 7684075
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.